Broadwood Capital Inc. Acquires 1,315,339 Shares of OncoCyte Co. (NASDAQ:OCX)

Broadwood Capital Inc. increased its holdings in OncoCyte Co. (NASDAQ:OCX - Free Report) by 26.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,244,405 shares of the company's stock after buying an additional 1,315,339 shares during the period. OncoCyte comprises approximately 1.2% of Broadwood Capital Inc.'s investment portfolio, making the stock its 6th biggest holding. Broadwood Capital Inc. owned about 37.10% of OncoCyte worth $14,862,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of OCX. Geode Capital Management LLC lifted its position in OncoCyte by 12.2% during the third quarter. Geode Capital Management LLC now owns 103,980 shares of the company's stock valued at $296,000 after acquiring an additional 11,289 shares during the last quarter. Pura Vida Investments LLC grew its stake in OncoCyte by 32.1% during the 4th quarter. Pura Vida Investments LLC now owns 654,451 shares of the company's stock worth $1,558,000 after buying an additional 159,106 shares during the last quarter. FNY Investment Advisers LLC increased its position in OncoCyte by 15.1% during the 4th quarter. FNY Investment Advisers LLC now owns 49,377 shares of the company's stock valued at $117,000 after buying an additional 6,481 shares in the last quarter. Finally, Two Sigma Securities LLC purchased a new stake in OncoCyte in the fourth quarter valued at about $31,000. Hedge funds and other institutional investors own 55.35% of the company's stock.

Analyst Upgrades and Downgrades

OCX has been the topic of several recent analyst reports. Lake Street Capital started coverage on shares of OncoCyte in a report on Friday, March 28th. They set a "buy" rating and a $5.00 price objective on the stock. StockNews.com assumed coverage on shares of OncoCyte in a report on Sunday, April 6th. They issued a "sell" rating for the company. Needham & Company LLC reissued a "buy" rating and set a $4.25 price objective on shares of OncoCyte in a report on Tuesday, April 8th. Finally, Stephens reissued an "equal weight" rating and issued a $4.00 target price on shares of OncoCyte in a research report on Tuesday, March 25th.

OncoCyte Stock Performance

NASDAQ OCX traded up $0.03 on Friday, reaching $2.87. 62,571 shares of the company's stock traded hands, compared to its average volume of 57,456. OncoCyte Co. has a fifty-two week low of $1.92 and a fifty-two week high of $4.75. The firm has a market cap of $82.08 million, a price-to-earnings ratio of -0.65 and a beta of 0.95. The stock has a 50 day moving average price of $3.17 and a 200-day moving average price of $2.70.

OncoCyte (NASDAQ:OCX - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.88. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. The firm had revenue of $1.49 million for the quarter, compared to the consensus estimate of $0.16 million. As a group, equities research analysts anticipate that OncoCyte Co. will post -2.57 EPS for the current fiscal year.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.